Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis

Hurley, Margaret M.; Smith, Sherie; Forrester, Douglas L; Smyth, Alan

doi:10.1002/14651858.cd008037.pub4

Cited by 8 publications

(7 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, clinical practice guidelines for their treatment should always be followed (24). Other bacteria present in these patients are: Stenotrophomonas maltophilia and Pseudomona aeruginosa; these bacteria should be treated based on clinical judgment (especially if found incidentally, as these bacteria are present in these patients and are resistant to antibiotics (25)(26)(27)(28). However, studies have reported that administration of inhalation antibiotics in Pseudomonas aeruginosa infection improves lung function and reduces the likelihood of exacerbations, especially with the use of Aztreonam over Tobramycin.…”

Section: Resultsmentioning

confidence: 99%

The Evolving Management of Cystic Fibrosis

García¹,

García²,

Gómez³

et al. 2022

EPRA

View full text Add to dashboard Cite

Introduction: Cystic fibrosis is a genetic pathological condition, affecting chromosome 7, which encodes the CFTR protein. This pathology is characterised by abundant mucus production, which in turn leads to blockage of the airways and blockage of the digestive tract. Objective: The aim of this literature review is to gather the largest available amount of information related to cystic fibrosis and analyse it in detail, indicating the results and expectations that have been had with the use of some drugs over time in patients with cystic fibrosis. It is also intended to mention updates of procedures and their effectiveness.Methodology: a systematic and complete search was carried out using the Cochrane Library database, with the term Cystic Fibrosis. The documents found were in Spanish and English. Some articles were excluded due to lack of updated information. Results: Inhalation Dornase alfa alfa is a useful drug for airway improvement and mucus viscosity reduction, as are bronchodilators. Pancreatic enzymes and ursodeoxycholic acid are beneficial in the gastrointestinal area, reducing intestinal symptomatology. In patients with diabetes, Insulin is preferred. Only glutathione has a beneficial effect in patients with cystic fibrosis. Rehabilitation and management of postural abnormalities is vital to improve patients' lives. In patients with nutritional deficiencies, nasogastric tube placement or gastrostomy is preferred to improve their nutrition. Conclusions: Cystic fibrosis is a disease that has an inevitable progression. The treatments studied here show that they only help quality of life and pulmonary and gastrointestinal functions temporarily. Further studies are needed to determine therapies that can significantly improve patients, both physically and psychologically; and who knows, some therapy or therapies that may lead to a cure for this disease.

show abstract

Section: Resultsmentioning

confidence: 99%

The Evolving Management of Cystic Fibrosis

García¹,

García²,

Gómez³

et al. 2022

EPRA

View full text Add to dashboard Cite

show abstract

“…Por lo que, siempre se deben seguir las guías de práctica clínica para el tratamiento de estas (24). Otras bacterias presentes en estos pacientes son: la Stenotrophomonas maltophilia y la Pseudomona aeruginosa; estas bacterias deben ser tratadas en base al criterio clínico (sobre todo, si se encuentra de manera incidental; puesto que, estas bacterias están presentes en este tipo de pacientes y son resistente a antibióticos (25)(26)(27)(28). Ahora bien, estudios han reportado que la administración de antibióticos por vía inhalatoria en una infección por Pseudomona aeruginosa, mejoran la función pulmonar y reducen la probabilidad de exacerbaciones, sobre todo con el uso de Aztreonam sobre la Tobramicina.…”

Section: E L M Y C O B a C T E R I U M A B S C E S S U S Y E Lunclassified

La evolución del manejo de la fibrosis quística. revisión bibliográfica

Pesántez

2022

Gac Méd Caracas

View full text Add to dashboard Cite

show abstract

“…Adjuvante antimikrobielle Therapien, welche im weitesten Sinne zu den komplementären Therapieverfahren gezählt werden können, wurden in wenigen Studien bei Mukoviszidose untersucht. Bisher konnten keine Belege gefunden werden, dass Beta-Carotene, Knoblauch, Zink oder KB001 einen positiven Effekt in Bezug auf die Lungenfunktion, die Exazerbationsrate oder die Lebensqualität besitzen [128].…”

Section: Welchen Stellenwert Haben Komplementäre Therapieverfahren Beunclassified

S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Modul 2: Diagnostik und Therapie bei der chronischen Infektion mit Pseudomonas aeruginosa

Schwarz

Schulte-Hubbert²,

Bend

et al. 2018

Pneumologie

View full text Add to dashboard Cite

Cystic Fibrosis (CF) is the most common autosomal-recessive genetic disease affecting approximately 8000 people in Germany. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leading to dysfunction of CFTR, a transmembrane chloride channel. This defect causes insufficient hydration of the epithelial lining fluid which leads to chronic inflammation of the airways. Recurrent infections of the airways as well as pulmonary exacerbations aggravate chronic inflammation, lead to pulmonary fibrosis and tissue destruction up to global respiratory insufficiency, which is responsible for the mortality in over 90 % of patients. The main aim of pulmonary treatment in CF is to reduce pulmonary inflammation and chronic infection. () is the most relevant pathogen in the course of CF lung disease. Colonization and chronic infection are leading to additional loss of pulmonary function. There are many possibilities to treat -infection. This is a S3-clinical guideline which implements a definition for chronic-infection and demonstrates evidence-based diagnostic methods and medical treatment for -infection in order to give guidance for individual treatment options.

show abstract

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis

Cited by 8 publications

References 67 publications

The Evolving Management of Cystic Fibrosis

The Evolving Management of Cystic Fibrosis

La evolución del manejo de la fibrosis quística. revisión bibliográfica

S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Modul 2: Diagnostik und Therapie bei der chronischen Infektion mit Pseudomonas aeruginosa

Contact Info

Product

Resources

About